NCT04925921已完成不适用
AVAVA SR-1 Wrinkles and BPL Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AVAVA, Inc.
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Improvement in facial wrinkles
研究概览
简要总结
This study is being conducted to evaluate the safety and efficacy of a laser called the SR-1 Skin Treatment System, or SR-1 Laser, for the treatment of wrinkles and pigmented spots. Participants will be treated with the SR-1 Laser 3 or 4 times with each treatment spaced 4-6 weeks apart. The improvement in wrinkles and pigmented spots will be evaluated 1 and 3 months after the final treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Wrinkles on both sides of the face (e.g., peri-oral, peri-orbital, and cheek) scored 4-9 on the Fitzpatrick Wrinkle and Elastosis Scale
- •Willingness to have both sides of the face exposed to the SR-1 Laser.
- •Willingness to have digital photographs taken of their face and agreement with use of photographs, with their identity protected, for presentation, educational, or marketing purposes.
- •Willingness to comply with the following during the study, including the follow-up period:
- •maintain consistent skin care regimen on treated areas
- •cover treated areas or have very limited sun exposure and use a provided sunscreen as directed by the Investigator
- •refrain from using systemic corticosteroids
- •refrain from using systemic or topical skin-lightening medications or retinoids
- •refrain from any other procedures in the treatment areas
- •Willingness and ability to comply with study instructions and return for required visits.
排除标准
- •Skin pathology or condition, or medication use that could interfere with evaluation of the study procedure, e.g.,
- •Isotretinoin use within previous 6 months
- •Surgical treatment in the target areas within previous 6 months
- •Active vitiligo, psoriasis, or eczema, or history of these in the treatment area
- •Injection of botulinum toxin in the treatment areas within the previous 3 months.
- •Facial cosmetic procedures in the target areas within previous 6 months (e.g., laser or other energy-based device treatment, microdermabrasion, microneedling, chemical peel, injection of dermal filler).
- •Current smoker or history of smoking greater than 0.5 pack/day in past 5 years.
- •Excessive sun exposure in the previous month, or unable or unlikely to refrain from tanning or excessive sun exposure during the study.
- •Artificial tanning (e.g., tanning bed or tanning lotion/spray) in the target areas within previous 1 month or intention to use artificial tanning during the study.
- •Active localized or systemic infection, or an open wound in area being treated.
- •History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid).
- •History of connective tissue disease, such as lupus or scleroderma.
- •History of seizure disorders due to light.
- •Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals sensitive to light may be used in other areas off-face).
- •History of gold therapy.
- •History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
- •History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer. Current cancerous lesion in the treatment area.
- •Pregnancy or lactation, or intent to become pregnant within the study period.
- •Significant uncontrolled concurrent illness, such as diabetes mellitus, hypertension, or cardiovascular disease.
- •History of immunosuppression/immune deficiency disorder or currently using immunosuppressive medications.
- •Planned weight loss of greater than five pounds.
- •Facial hair in the treatment areas which would prevent evaluation of the outcome measures.
- •Current enrollment in a clinical study of any other investigational drug or device, or has received an investigational drug or been treated with an investigational device within 6 months prior to entering this study, unless the other clinical study only involves noninvasive imaging.
- •Any other physical or mental condition, or laboratory value, that would, in the professional opinion of the Investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.
结局指标
主要结局
Improvement in facial wrinkles
时间窗: 3 months after the final treatment
A 1 point or greater reduction in facial wrinkle severity using the Fitzpatrick Wrinkle and Elastosis Scale (FWS), as assessed, and agreed upon by at least two of three blinded independent reviewers in at least 70% of subjects as determined with a side-by-side evaluation of baseline and post-treatment photographs. The FWS scores range from 1 to 9 with lower numbers representing less severe wrinkles.
次要结局
- Tolerance of procedure(during treatment)
- Adverse Events(3 months after the final treatment)
- Subject satisfaction with the improvement in wrinkles(1 and 3 months after the final treatment)
- Subject satisfaction with the improvement in BPL(1 and 3 months after the final treatment)
- Overall improvement(1 and 3 months after the final treatment)
- Reduction of pigmentation in benign pigmented lesions (BPL)(3 months after the final treatment)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
The MIRIA Acne Scar StudyAcne Scars - Mixed Atrophic and HypertrophicNCT05597267AVAVA, Inc.75
招募中
不适用
A Study of a Laser for the Treatment of Acne VulgarisAcne VulgarisNCT05430464Cutera Inc.30
已完成
不适用
Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal AtrophyVulvovaginal AtrophyNCT02085980El. En. SpA30
撤回
不适用
Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic AlopeciaAndrogenetic AlopeciaNCT05129254Montefiore Medical Center
已完成
4 期
Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic EyesMyopiaPresbyopiaHyperopiaNCT01387360Technolas Perfect Vision GmbH33